UNSPSC 51313115: Chlorcyclizine monohydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H21ClN2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NPB7A7874U, chemically known as piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-methyl-, monohydrochloride, but more generally known as chlorcyclizine monohydrochloride, which bears US NIH Compound Identifier 62413. European Medicines Agency schedules chlorcyclizine monohydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06178MIG.

Most nations, for tariff purposes, schedule chlorcyclizine monohydrochloride under HS 29335995. SMILES: CN1CCN(CC1)C(C2CCCCC2)C3CCC(CC3)CL.CL.

UNSPSC 51313115 Chlorcyclizine monohydrochloride is a Commodity code with minimal recent state and local procurement activity specifically matched to this chemical compound. The three recent opportunities recorded under this code involve naloxone procurement, direct-to-manufacturer pharmacy programs, and generic multi-source pharmaceuticals—none of which directly center on chlorcyclizine monohydrochloride. State and local governments posting under this code are acquiring pharmaceutical products through health departments, cooperative purchasing alliances, and health and human services commissions, but the code appears to serve as a broad catch-all for pharmaceutical commodities rather than reflecting procurement demand for this specific active ingredient.

Issuing bodies soliciting pharmaceutical products include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and participating jurisdictions). Recent opportunities include Seminole County's IFB60459723LAS for naloxone and drug deactivation systems due July 26, 2023 with 1,900 units of naloxone and 800 deactivation systems required annually; Texas HHS's RFI HHS0017013 posted April 3, 2026 to explore direct-to-manufacturer prescription capabilities; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 posted January 20, 2026 with proposals due March 26, 2026 for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson. Geographic activity spans Florida, Texas, Minnesota, and Oregon, though the code shows limited specificity to chlorcyclizine monohydrochloride itself.